JP2025102940A5 - - Google Patents

Info

Publication number
JP2025102940A5
JP2025102940A5 JP2025061710A JP2025061710A JP2025102940A5 JP 2025102940 A5 JP2025102940 A5 JP 2025102940A5 JP 2025061710 A JP2025061710 A JP 2025061710A JP 2025061710 A JP2025061710 A JP 2025061710A JP 2025102940 A5 JP2025102940 A5 JP 2025102940A5
Authority
JP
Japan
Prior art keywords
cancer
crystalline form
pyridin
dicarboxamide
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025061710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025102940A (ja
Filing date
Publication date
Priority claimed from JP2022515704A external-priority patent/JP2022546861A/ja
Application filed filed Critical
Publication of JP2025102940A publication Critical patent/JP2025102940A/ja
Publication of JP2025102940A5 publication Critical patent/JP2025102940A5/ja
Pending legal-status Critical Current

Links

JP2025061710A 2019-09-10 2025-04-03 マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用 Pending JP2025102940A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962898469P 2019-09-10 2019-09-10
US62/898,469 2019-09-10
JP2022515704A JP2022546861A (ja) 2019-09-10 2020-09-09 マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用
PCT/US2020/049986 WO2021050580A1 (en) 2019-09-10 2020-09-09 Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022515704A Division JP2022546861A (ja) 2019-09-10 2020-09-09 マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用

Publications (2)

Publication Number Publication Date
JP2025102940A JP2025102940A (ja) 2025-07-08
JP2025102940A5 true JP2025102940A5 (https=) 2025-08-21

Family

ID=74866002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515704A Pending JP2022546861A (ja) 2019-09-10 2020-09-09 マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用
JP2025061710A Pending JP2025102940A (ja) 2019-09-10 2025-04-03 マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022515704A Pending JP2022546861A (ja) 2019-09-10 2020-09-09 マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用

Country Status (6)

Country Link
US (1) US12466838B2 (https=)
EP (1) EP4027999B1 (https=)
JP (2) JP2022546861A (https=)
CN (1) CN114401720A (https=)
CA (1) CA3150267A1 (https=)
WO (1) WO2021050580A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101125932B1 (ko) 2006-12-06 2012-03-22 아이디유엔 파마슈티칼즈, 인코포레이티드 (3s)-3-[n-(n'-(2-tert-부틸페닐)옥사밀)알라니닐]아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
US8907091B2 (en) * 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
US20180237378A1 (en) * 2015-08-19 2018-08-23 Sandoz Ag Asymmetric Bisamidation of Malonic Ester Derivatives
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物

Similar Documents

Publication Publication Date Title
JP2025102940A5 (https=)
TWI736570B (zh) Egfr抑制劑游離鹼或其酸式鹽的多晶型、其製備方法和應用
AU2004299413B2 (en) Novel oxazolidinone derivatives
CN118451081A (zh) Kras抑制剂的多晶型物及其制备方法和用途
CA3142069A1 (en) Aurora kinase inhibitor and use thereof
JPWO2008133274A1 (ja) 環式基で置換されたアミノジヒドロチアジン誘導体
JP2023082086A5 (https=)
CN109863137B (zh) Lsd1抑制剂及其医学用途
JP4142621B2 (ja) 純結晶形態の5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニルおよび合成方法
TW201309694A (zh) 醫藥活性物質的固態形式
JP2019516749A5 (https=)
JP2020517611A5 (https=)
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
KR102886764B1 (ko) Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
RU2021132394A (ru) Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
JP2011515421A5 (https=)
JPWO2021050580A5 (https=)
CN101277694A (zh) 盐酸伊立替康的新晶形
JPWO2023022912A5 (https=)
JPWO2020118113A5 (https=)
JP2021522348A5 (https=)
WO2005080381A1 (en) New polymorphic forms of ondansetron, processes for preparing them, pharmaceutical compositions containing them and their use as antiemetics
IL305788A (en) A crystalline salt of a multityrosine kinase inhibitor, a method for its preparation and its use
US20070105885A1 (en) Novel crystalline polymorphic form of a camptothecin analogue